Toxicological implication of prostaglandin transporter SLCO2A1 inhibition by cigarette smoke in exacerbation of lung inflammation.


Journal

Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575

Informations de publication

Date de publication:
15 10 2020
Historique:
received: 24 05 2020
revised: 11 08 2020
accepted: 14 08 2020
pubmed: 24 8 2020
medline: 12 1 2021
entrez: 24 8 2020
Statut: ppublish

Résumé

We reported that bleomycin (BLM)-induced pulmonary fibrosis was exacerbated in the prostaglandin transporter gene (Slco2a1)-deficient mice (Slco2a1(-/-)). Because cigarette smoke (CS) contributes to creating a profibrotic milieu in the respiratory region, the present study aimed to investigate the impact of CS on SLCO2A1-associated pathogenesis in the lungs of BLM-instilled mice. Bronchoalveolar lavage (BAL) fluid cell analysis indicated more severe inflammation in Slco2a1(-/-) on day 5 after BLM intratracheal instillation, and Slco2a1 deletion increased mRNA expression of pro-inflammatory cytokines (Tnf-α and Il-1β) and chemokine (Ccl5) in BAL cells. Male Slco2a1(-/-) exhibited significantly higher amounts of released Il-1β in BAL fluid, compared with female Slco2a1(-/-), male or female Slco2a1(+/+) group. The amount of PGE

Identifiants

pubmed: 32828905
pii: S0041-008X(20)30327-6
doi: 10.1016/j.taap.2020.115201
pii:
doi:

Substances chimiques

Cytokines 0
Organic Anion Transporters 0
Slco2a1 protein, mouse 0
Tobacco Smoke Pollution 0
Bleomycin 11056-06-7
Dinoprostone K7Q1JQR04M

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115201

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest There is no conflict of interest to report.

Auteurs

Takeo Nakanishi (T)

Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Japan. Electronic address: nakanishi@takasaki-u.ac.jp.

Shiori Sakiyama (S)

School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa 920-1192, Japan.

Hiroki Takashima (H)

School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa 920-1192, Japan.

Ryokichi Honda (R)

School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa 920-1192, Japan.

Melody N Shumba (MN)

Depatiment of Nutrition, Faculty of Health and Welfare, Takasaki University of Health and Welfare, Takasaki, Japan.

Yoshinobu Nakamura (Y)

Faculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki, Japan.

Kazuo Kasahara (K)

School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-0934, Japan.

Ikumi Tamai (I)

School of Pharmaceutical Sciences, Kakuma-machi, Kanazawa 920-1192, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH